Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration

Recruiting now · Phase 4

Conditions studied: Macular Degeneration Choroidal Neovascularization

In brief

We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.

Key facts

Study ID

NCT06742307

Run by

Hospital Authority, Hong Kong

People needed

40

Starts

2025-08-21

Expected to finish

2027-02-01

Last updated by the study team

2025-10-01

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3.

You may not qualify if…

• eyes that received any anti-VEGF therapy in the prior six months,
• eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation),
• concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period.

Where it is running

• Department of Ophthalmology, United Chrisitian Hospital — Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.